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Summary  
Fibronectin, a large extracellular glycoprotein, mediates the interaction of cells with the extracellular matrix. 
Heterogeneity in the structure of fibronectin is largely due to the alternative splicing of three exons (IIIB, II IA and V) 
during processing of the fibronectin primary transcript. Osteoarthritis, a degenerative disease of synovial joints, is 
characterized by a progressive loss of the articular cartilage ventually resulting in pain and loss of joint function. In 
contrast o the loss of most cartilage matrix proteins accompanying this process, osteoarthritic cartilage contains more 
fibronectin than disease-free cartilage. We examined the splicing patterns of fibronectin mRNA from adult human 
articular cartilage of normal and osteoarthritic joints by RNase protection (exon IIIA and exon IIIB) and reversed 
transcription-polymerase chain reaction (exon V) assays to determine whether or not the increased fibronectin content 
in osteoarthritic cartilage is also associated with differences in the splicing patterns of these three alternatively spliced 
exons. The results revealed no gross differences in splicing of these exons between the fibronectin mRNA isolated from 
adult human articular normal and osteoarthritic cartilage. Thus alterations in the structure of cartilage fibronectin do 
not appear to correlate with the increased level of fibronectin protein associated with osteoarthritis. 
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I n t roduct ion  
FIBRONECTIN, A LARGE extrace l lu lar  glycoprotein,  
par t ic ipates  in a wide var iety  of ce l lu lar  act iv i t ies 
inc luding di f ferent iat ion,  adhesion,  and migrat ion.  
These act iv it ies resul t  from the abi l i ty of the 
f ibronect in d imer to in teract  with a number  of 
b io logical  s t ruc tures  such as the cell surface, 
col lagen, f ibrin and hepar in .  Therefore, f ibronect in 
pr imar i ly  funct ions as a connect ing molecule in the 
extrace l lu lar  matr ices  of t issues by mediat ing  both 
ce l l -matr ix  and matr ix -matr ix  in teract ions  [for 
reviews, see 1,2]. Versat i l i ty in funct ion of 
the f ibronect in mo lecu le  may par t ia l ly  resul t  
f rom the heterogeneous  s t ruc ture  of the f ibronect in 
monomer.  Heterogene i ty  in the f ibronect in 
monomer  is largely due to the a l ternat ive spl ic ing of 
at least three exons* (IIIB, I I IA  and V) dur ing the 
post - t ranscr ipt iona l  process ing of its p r imary  
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*Hereafter we will use the term 'exon' to refer not only to a 
coding segment of the fibronectin gene, but also to the 
comparable s gment of the mRNA and protein. 
t ranscr ip t  [3-5]. Two of the a l ternat ive ly  spl iced 
exons ( I I IB and I I IA)  can e i ther  be ent i re ly  present  
or ent i re ly  absent in the mature  f ibronect in mRNA 
as a resu l t  of  a form of a l ternat ive spl ic ing known 
as exon sk ipping [for reviews, see 1, 2]. The th i rd  
a l ternat ive ly  spl iced exon (V, for var iable region)  
can have mult ip le  spl ice var iat ions  involv ing exon 
subdivis ion with the number  of possible var ia t ions  
depending on the species [for reviews, see 1, 2]. 
Cart i lage, a specia l ized connect ive t issue 
of joints, is composed pr imar i ly  of ext race l lu la r  
matr ix  components  found a lmost  exclusively in this  
tissue. These dist inct  cart i lage ext race l lu lar  matr ix  
prote ins include type I I ,  IX and XI co l lagens 
[reyiewed in 6, 7] as well as aggrecan,  the large 
aggregat ing chondro i t in /keratan  sulfate proteogly-  
can [reviewed in 7]. F ibronect in  also appears  
th roughout  he cart i lage matr ix  [10-14] a l though its 
p r imary  funct ion in this t issue is not ent i re ly  known 
at this time. The s t ruc ture  of cart i lage f ibronect in,  
however, may differ f rom the f ibronect in in o ther  
cells and t issues since it must  in teract  wi th  the 
unique components  of the  cart i lage ext race l lu la r  
matr ix.  For example, we have shown prev ious ly  that  
several  chick embryonic  cart i lages (vertebral ,  
s terna l  and t ib iotarsa l )  conta in  an unusua l  form of  
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fibronectin mRNA resulting from specific alterna- 
tive splicing events [13]. Specifically, virtually all of 
the fibronectin mRNA from these chick cartilages 
contain exons IIIB and V, but do not contain exon 
IIIA (B+A-V+). In contrast, most of the fibronectin 
mRNA from other cells or tissues of mesenchymal 
origin, contain exons IIIA and V but not exon IIIB 
(B-A+V+). Hypothetically, specific structural 
modifications resulting from mRNA alternative 
splicing in cartilage fibronectin may tailor the 
molecule to specifically interact with the special- 
ized components of the cartilage extracellular 
matrix. 
Osteoarthritis (OA) is a degenerative disease of 
synovial joints. In the fully developed condition, 
loss of articular cartilage occurs from part or all of 
the joint surface, resulting in pain and loss of joint 
function. In contrast o the general degeneration of
the cartilage matrix accompanying the progression 
of the disease, the cartilage matrix from human 
[15, 16], canine [17, 18] and rabbit [18] osteoarthritic 
joints contains more fibronectin than cartilage from 
disease-free joints. Immunoreactivity with exon- 
specific antibodies uggests that the fibronectin in 
adult human articular cartilage from osteoarthritic 
joints appears to contain 0.7-6.0% exon IIIA and 
5 30% exon IIIB [19]. However, the structure of 
human cartilage fibronectin in the normal joint is 
presently not known. We have compared the 
structure of fibronectin mRNA from adult human 
articular cartilage of normal and osteoarthritic 
joints in order to determine whether the associated 
increase in fibronectin content in the disease-state 
also accompanies changes in fibronectin structure 
resulting from alternative mRNA splicing. 
Mater ia l s  and  methods  
PARENTPLASMIDS 
The plasmid pFH111 [20], containing approxi- 
mately 2 kb of human fibronectin cDNA including 
the 270 bases encoding the EDA 1 domain as well as 5' 
and 3' flanking cDNA, was obtained from American 
Type Culture Collection (Rockville, MD, U.S.A.). 
The AccI fragment of 2F2 [21], subcloned into M13, 
was generously provided by Dr Luciano Zardi 
(Istituto Nazionale per la Ricerca sul Cancro, 
1The abbreviations used are: DMEM, Dulbecco's modified 
Eagle's medium; EDA, extra domain A or the region encoded by 
exon IIIA in the human fibronectin gene; EDB, extra domain B or 
the region encoded by exon IIIB in the human fibro- 
nec~in gene; FBS, fetal bovine serum; PBS, phosphate buffered 
saline; PCR, polymerase chain reaction; pen, penicillin G; Pipes, 
piperazine-N, N'-bis(2-ethanesulfonic acid); RT-PCR, reverse 
transcription-polymerase chain reaction; and strep, strepto- 
mycin sulfate. 
Genova, Italy). The AccI fragment contains 792 
bases of human fibronectin cDNA including 14 
bases encoding the last 5 amino acids of the type 
III-6 repeat, 279 bases encoding the entire type III-7 
repeat, 273 bases encoding the entire EDB domain 
(exon IIIB), and 226 bases encoding the first 75 
amino acids of the type III-8 repeat. 
PREPARATION OF RNASE PROTECTION PROBES 
The parent plasmids described above, pFH111 and 
the ~F2 fragment, were used as DNA templates in 
separate polymerase chain reactions (PCR) to 
generate the cDNA fragments, phuA and phuB (see 
Fig. 1), respectively. Table I shows the specific 
oligonucleotide primers used in each PCR reaction. 
The restriction enzyme sites (underlined) were 
inserted at the 5' end of each oligonucleotide primer 
in order to incorporate different restriction enzyme 
sites at each end of the final PCR product for 
directional subcloning into pGEM2 (Promega 
Biotec). The pFHl l l  plasmid and the 2F2 fragment 
(200 ng of each) were subjected to 35 cycles (1 min, 
94°C; 2 min, 55°C; 3min, 72°C) of amplification 
using a GeneAmp kit (Perkin-Elmer Cetus) in the 
presence of 25 pmol of the appropriate oligonucleo- 
tide primers (see Table I). The resulting PCR 
products were electroeluted from a 2% agarose gel 
onto NA-45 paper (Schleicher and Schuell). The 
bands were eluted from the paper into elution buffer 
(IM NaC1, 0.1 mM EDTA, 20 mM Tris, pH 8) at 65°C 
during a 20 min incubation. The electroeluted PCR 
products were then digested with Eco R1 and Bam 
H1, and ligated into the Eco R1 and Bam H1 sites of 
pGEM2 overnight with T4 ligase (Pharmacia) at 
15°C. The resulting constructs, phuA and phuB, 
were utilized in in vitro transcription reactions as 
described below to prepare uniformly labeled RNA 
probes for RNase protection assays. The phuA 
plasmid contains 575 bases of human fibronectin 
cDNA including 164 bases of the type III-10 repeat, 
all 270 bases of the type III-11 repeat, and 141 bases 
of exon IIIA. The phuB plasmid contains 410 bases 
of human fibronectin cDNA including 13 bases of 
the type III-6 repeat, all 279 bases of the type III-7 
repeat, and 118 bases of exon I I IB. 
RNA ISOLATION FROM ADULT HUMAN ARTICULAR 
CARTILAGE 
Adult human articular cartilage was obtained 
from femoral heads of hip joints of the femoral 
condyle and tibial plateau of knee joints discarded 
during routine or trauma-related joint arthroplasty. 
Samples were obtained by removing all remaining 
original art icular cartilage from the surface of the 
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FIG. 1. Probes used in nuclease protection assays for the analysis of fibronectin mRNA alternative splicing. The schematic 
diagram represents the arrangement of type III repeats and the exons known to be involved in alternative splicing for 
a portion of the fibronectin gene. The numbered white boxes represent individual type III repeats; all of the repeats, except 
number 9, are composed of two separate xons. The dark shaded boxes represent he exons that are known to be 
alternatively spliced (IIIB, I I IA and V). The composition of the two human-specific cDNAs used as probes in the nuclease 
protection assays are shown below the schematic diagram. The relative expected sizes of the mRNA fragments protected 
by each probe in nuclease protection assays are also shown. 
femoral  head of the hip or the femoral  condyle and 
t ib ia l  p la teau of the knee being par t icu lar ly  careful  
to avoid any osteophyt ic  art i lage present  on the 
jo int  surfaces. A cart i lage sample was cons idered 
'normal '  if the pat ient  was over the age of 50 and 
displayed no radiologic or cl inical signs of OA and 
'probable normal '  if the pat ient  was over the age of 
25 with no family h is tory  of OA. The sever i ty of 
os teoar thr i t i c  cart i lages was classif ied on the basis 
of radiologic determinat ions  [22]. The age, sex of the 
pat ient,  cart i lage locat ion,  reason for surgery and 
sever i ty of the disease for each pat ient  are displayed 
in Table III. 
Cart i lage samples  were e i ther  processed for 
chondrocyte  iso lat ion or snap-frozen in l iquid 
n i t rogen as soon as possible after  ext ract ion  from 
the jo int  (within lh ) .  RNA was isolated e i ther  
indirect ly  by iso lat ion of chondrocytes  from the 
cart i lage t issues dur ing an overn ight  t rypsin/  
co l lagenase digest ion pr ior  to poly(A)+ RNA 
isolat ions from the l iberated chondrocytes  [23] or 
direct ly from the cart i lage using density gradient  
centr i fugat ion in ces ium t r i f luoroacetate  [24] as 
descr ibed below. 
Chondrocyte isolation/poly(A)+ RNA preparation 
Chondrocytes  were isolated from cart i lage 
samples basical ly  as descr ibed previous ly  [23]. 
Specifically, the cart i lage t issues were r insed twice 
in phosphate  buffered sal ine (PBS) conta in ing  
50 units /ml  penici l l in G and 50 mg/ml s t reptomycin  
sulfate (1 x pen/strep;  Gibco/BRL),  0.5 mcg/ml  am- 
photer ic in  B (2 x fungizone; Gibco/BRL),  weighed 
and minced into small  pieces. The minced t issue was 
then incubated in PBS conta in ing lxpen/s t rep ,  
l x fung izone  and 0.5 mg/ml  hya luron idase (Wor- 
th ington Biochemicals)  for 5-10 min at 37°C with 
rocking. The t issue was r insed twice with PBS 
conta in ing 1 × pen/strep and I x fungizone and was 
then incubated in the same solut ion conta in ing 
2mg/ml  t ryps in  (Worth ington Biochemicals)  and 
2 mg/ml col lagenase (Worth ington Biochemicals)  
for 1 h at 37°C with rocking. The t issue and cells 
were washed by centr i fugat ion with PBS conta in ing 
i x pen/strep and i x fungizone and then p laced in 
30ml  Dulbecco's  Modif ied Eagles'  Med ium 
(DMEM; Gibco/BRL) conta in ing 10% fetal bovine 
serum (FBS; Hyclone), I x pen/strep, I x fungizone, 
and 0.5 mg/ml  col lagenase. The suspens ion was 
Table I 
Oligonucleotide primers 
Primer name Exon location Sequence 
VB105 5' primer III-10 repeat 
VB106 3' primer Exon IIIA 
VB202 5' primer III-6 repeat 
VB201 3' primer Exon IIIB 
TCAGAATTCGAGGAAATAGCCCTGTCCAGGAG 
AGTGGATCCGAATAGCTCATGGATTCCATCCTC 
TCAGAATTCCAAAGTGGTGACACCATTGTCTCC 
AGTGGATCCCCGCAACTACTGTGATGCGGTAC 
Polymerase chain reactions were run in the presence of pFH111 plasmid as template and VB105 and VB106 
oligonucleotide primers to generate the phuA fragment, kF2 served as the template for PCR with VB202 and 
VB201 oligonucleotide primers to generate the phuB fragment. All primers are oriented 5' to 3'. Restriction 
enzyme sites are underlined. 
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rocked slowly overnight (18 h) in a 37°C incubator, 
5% CO2. On the following day, the medium 
containing the isolated cells was diluted to 80 ml 
with DMEM/FBS and the cells collected by 
centrifugation at 1500 rpm for 15 min. The cells were 
washed once with DMEM/FBS, filtered through a 
cell strainer (Becton-Dickinson) and counted. 
Poly(A)+ RNA was isolated from the cells using a 
QuickPrep mRNA kit (Pharmacia) as directed by 
the manufacturer• 
CsTFA isolations 
Total RNA was isolated directly from human 
adult articular cartilage basically as described [24]. 
Specifically, cartilage tissues were pulverized into a 
powder under liquid nitrogen in a mortar and pestle• 
The frozen cartilage powder was immediately 
homogenized in 4 M guanidine thiocyanate, 0•1 M 
Tris-HC1, pH 7.5, and 1% fl-mercaptoethanol using 
a Tissue-tek microfine probe at high speed for 
1-2 min. Sodium lauryl sarcosine was added to 0.5% 
and the sample centrifuged at 3000 g for 15 min in a 
Sorvall SS34 rotor• The resulting supernatant was 
layered over a 2 ml cushion of 1.60 g/ml CsTFA, 1 mM 
EDTA (pH 8.0) in Beckman polyallomer centrifuge 
tubes (14 x 89 mm). The samples were centrifuged at 
18°C for 18 h at 35 000 rpm in a Beckman SW41 Ti 
rotor• Following ultracentrifugation, most of the 
supernatant was removed by aspiration to within 
1 cm of the bottom of the tube. The remainder was 
decanted carefully from the tube while not 
disrupting the RNA pellet• The bottom of the tube 
was cut off and the RNA pellet was dissolved in 
DEPC-treated water• The RNA was ethanol-preci- 
pated, washed and redissolved in 50 ttl DEPC- 
treated water. 
RNASE PROTECTION ASSAYS 
RNase protection assays using human-specific 
probes for exon IIIA and exon IIIB were performed 
as described previously [13]. Specifically, the phuA 
and phuB plasmids were linearized with Eco R1 and 
transcribed with T7 polymerase (Promega Biotec) as 
described [25]. The transcription reactions were 
t-hen incubated with 10 units of RNase-free DNase 
(Promega Biotec) for 15 min at 37°C to remove the 
template DNA. The uniformly labeled RNA 
resulting from the in vitro transcription of each 
plasmid was dissolved in 100 pl of hybridization mix 
(80% formamide, 40 mM Pipes, pH 6.4, 0.4 M NaC1, 
1 mM EDTA). An aliquot (5 pl) containing approxi- 
mately 4 x 10 ~ dpm of radioactive RNA was added to 
total cellular RNA or poly(A)+ RNA (1-10 pg). Yeast 
tRNA was added to each reaction to maintain a 
constant amount of RNA (30 pg) in each sample• 
Samples were heated for 10min at 85°C and 
hybridized overnight at 65°C. Unhybridized RNA 
was digested for 30 min at 30°C in 250 pl of RNase 
digestion buffer (50raM Tris-HC1, pH 7.5, 0.5M 
NaC1) containing 40 Flg/ml RNase A (Sigma) and 
2 pg/ml RNase T1 (Bethesda Research Labora- 
tories)• Proteins were removed by phenol extraction• 
The protected RNA fragments were ethanol 
precipitated and dissolved in 10 #l of TE (10 mM 
Tris-HC1, pH 8.0, 1 mM EDTA). Formamide loading 
buffer (10pl; 89% deionized formamide, l mM 
EDTA, 0.3% xylene cyanol, 0.3% bromphenol blue) 
was added to 5 tL1 of each RNA sample• The samples 
were boiled for 3 min and subjected to electrophor- 
esis through an 8% polyacrylamide g l containing 
8 M urea. The resulting gels were subjected to 
autoradiography. The relative band intensities were 
determined by scanning with an LKB Ultrascan XL 
enhanced laser densitometer (Pharmacia/LKB 
Instruments) and then were corrected for the size of 
the protected fragments• The sizes of the protected 
RNA fragments were determined by comparison of 
their mobilities with fragments of pGEM3 digested 
with Hinf I, Rsa I and Sin I (Promega Biotec). 
REVERSE TRANSCRIPT ION-POLYMERASE CHAIN 
REACTION ASSAYS 
An RT-PCR approach [26] was utilized to 
determine the exon V splicing pattern of fibronectin 
mRNA from adult human articular cartilage• 
Specifically, primer extension reactions (reverse 
transcription) proceeded as described previously 
[27] using a 3' oligonucleotide primer from the 
type 1-10 repeat of the human fibronectin gene 
(5'-TTTAAAGCCTGATTCAGACATTCGTT-3') .  
The primer extension products were then subjected 
to 35 cycles (1 min, 94°C; 2 min, 55°C; 3 min, 72°C) of 
amplification using a GeneAmp kit (Perkin-Elmer 
Cetus) in the presence of 25pmol of the 
3' oligonucleotide primer described above and a 
5' oligonucleotide primer from the type III-14 repeat 
of the human fibronectin gene (5'-GGGAACCGAA- 
TATACAATTTATGTCA-3'). The resulting RT-PCR 
products were then separated by size on a 2% 
agarose gel and visualized by ethidium bromide 
staining• 
Resu l ts  
F IBRONECTIN  mRNA SPL IC ING PATTERNS FOR EXON I I IA 
AND EXON II IB IN ADULT HUMAN ART ICULAR 
CARTILAGE FROM OSTEOARTHRIT IC  JO INTS 
Immunoreactivity with exon-specific antibodies 
suggests that the fibronectin in adult human 
Osteoarthrit is and Cartilage Vol. 3 No. 3 191 
(a) 
1 2 3 4 
(b) 
+B 
-B  
I+A 
:? ? :: ~:::~i . . . . .  :] -A 
1 2 3 4 
FIG. 2. RNase protection assay analysis of exon IIIA and 
exon IIIB splicing patterns in fibronectin mRNA from 
adult human normal and osteoarthritic cartilage. 
Uniformly labeled T7 transcripts (phuB and phuA) of the 
plasmids hown in Fig. i were hybridized to total cellular 
or poly(A)+ RNAs from various human cartilage tissues. 
Unhybridized RNAs were digested with RNases A and T1, 
and the resulting protected fragments were subjected to 
electrophoresis through an 8% polyacrylamide gel 
containing 8 M urea as described under Materials and 
Methods. (a) RNase protection assays with the probe from 
plasmid phuB indicating the splicing pattern of exon IIIB. 
(b) Same as in (a) for the probe from phuA corresponding 
to the splicing pattern for exon IIIA. The largest protected 
fragment in each panel corresponds tofibronectin mRNAs 
containing the entire indicated exon, whereas the 
shortest fragment represents those mRNAs in which the 
entire exon is excluded. All of the protected fragments 
indicated as -B in (a) have been identified as I I IB- species 
[27]. 
pr ior  to poly(A)+ RNA iso lat ion from the l iberated 
chondrocytes.  RNase  protect ion  assays (Fig. 2 and 
Table II) us ing RNA isolated in this manner  reveal  
that  4.4 + 0.6% and 25.6 + 7.9% of the f ibronect in  
mRNA from human chondrocytes  i o lated f rom the 
adult  a r t i cu la r  cart i lage of os teoar thr i t i c  jo ints  
conta in  exon I I IA  and exon I I IB, respectively. Thus  
the spl ic ing pat terns  of the f ibronect in mRNA from 
the adult  human ar t i cu la r  cart i lage of os- 
teoaf thr i t i c  jo ints  appear  to cor re late  wi th  the 
s t ructure  of f ibronect in at the prote in  level. 
To rule out the possibi l i ty of ar t i facts  resu l t ing  
from the overn ight  iso lat ion of chondrocytes  f rom 
the human cart i lage samples pr ior  to RNA isolat ion, 
we als0 per formed direct  RNA isolat ions of tota l  
RNA from the adult  human ar t i cu la r  cart i lage of 
osteoarthr i t i c  jo ints  us ing the ces ium tr i f luoro- 
acetate  density gradient  centr i fugat ion procedure  
[24]. The spl ic ing pat terns  for exon I I IA  and exon 
I I IB from tota l  RNA isolated direct ly from adul t  
human ar t i cu la r  cart i lage of osteoar thr i t i c  jo ints  
(4.4 ± 0.6% and 31.2 _+ 3.6%, respectively) appear  to 
be ident ical  to the spl ic ing pat terns  for exon I I IA  
and exon I I IB from poly(A)+ RNAs iso lated 
indirect ly from the chondrocytes  of adult  human 
ar t i cu la r  cart i lage (4.4 + 0.6% and 25.6 ± 7.9%, 
respectively)% Thus, the procedure  for iso lat ing the 
RNA from the cart i lage samples does not appear  to 
affect the f ibronect in mRNA spl ic ing pat terns  for 
exon I I IA  or exon IIIB. Because these two RNA 
ar t icu lar  cart i lage from osteoarthr i t i c  jo ints  
appears  to conta in 0.7-6.0% exon I I IA  and 5-30% 
exon I I IB [19]. In order  to determine whether  or not 
the previously  reported prote in  in format ion corre- 
lates with mRNA data, we have determined the exon 
I I IA  and exon I I IB spl ic ing pat terns  of f ibronect in 
mRNAs from adult  human ar t i cu la r  cart i lage from 
osteoarthr i t i c  joints. This analys is  ut i l ized nuclease 
protect ion assays with human-speci f ic  probes for 
the a l ternat ively spl iced exons I I IA  and I I IB  
( labeled phuA and phuB, respectively, in Fig. 1). The 
largest  protected f ragment  in each exper iment  
corresponds to f ibronect in mRNA conta in ing the 
ent i re indicated exon whereas  the shortest  f ragment  
represents  mRNA in which the ent i re exon is spl iced 
out. 
In i t ia l ly  for this study, we isolated RNA from 
adult  human ar t i cu la r  cart i lage indirect ly by 
isolat ing the chondrocytes  from the intact  cart i lage 
dur ing an overnight  t ryps in/co l lagenase digest ion 
2Statist ical ly conf i rmed by ANOVA analys is .  
Table II 
Exon IIIA and exon IIIB splicing patterns of 
fibronectin mRNAs isolated from human chondrocytes 
or intact articular cartilages of osteoarthritic joints 
Tissue/sample IIIB+ (%) IIIA+ (%) 
Human chondrocytes from osteoarthritic joints 
OA-1 33.5 3.7 
OA-2 17.6 5.0 
Average +_ S.D. 25.5 + 7.9% 4.4 ± 0.6% 
Cartilages from osteoarthritic joints 
OA-3 22.6 5.5 
OA-4 ~- 43.4 2.5 
OA-5 41.2 2.7 
OA-6 24.9 6.1 
OA-7 25.3 3.8 
OA-8 29.6 5.5 
Average _+ S.D. 31.2 _+ 3.6% 4.4 _+ 0.6% 
RNAse protection assays were performed as described 
under Materials and Methods. Data are xpressed as the 
percentage of fibronectin mRNA in each sample that 
contains the entire indicated exon; the remainder of the 
mRNA has the entire exon spliced out. Each sample 
represents he RNA derived from the hip or knee articular 
cartilage of one individual patient. All values have been 
corrected for the size of the protected fragments. 
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Table III 
Exon IIIA and exon IIIB splicing patterns of fibrot~ectin mRNAs from various human articular cartilages 
Tissue/sample Diagnosis Age Sex Severity IIIB+ (%) IIIA+ (%) 
Osteosarcoma/amputation 28 M 0 
Avascular necrosis 34 F 0 
Avascular necrosis 37 M 0 
Pathological bone fracture/metastatic lung cancer 49 M 0 
Intracapsular f acture 67 M 0 
Subcapital displaced fracture 76 M 0 
Nonunion/intertrochanteric f acture of femur 95 M 0 
N-1 hip 
N-2 hip 
N-3 hip 
N-4 hip 
N-5 hip 
N-6 hip 
N-7 hip 
Normal average + S.D. (N = 7) 
OA-1 hip Spinal arthropathy/OA 42 F 3 
OA-2 knee Unicompartmental OA 47 F 3 
OA-3 knee OA 65 F 2 
OA-4 knee OA 66 M 3 
OA-5 knee Bilateral OA 66 M 4 
OA-6 knee Bilateral OA 68 F 4 
OA-7 knee Standard OA 71 F 4 
OA-8 hip OA 88 F 4 
OA average ± S.D. (N = 8) 
41.3 3.4 
31.2 3.4 
24.9 2.0 
29.8 3.5 
30.7 8.2 
24.3 5.4 
16.2 2.9 
28.3 ± 7.7% 4.1 ± 2.1% 
25.3 3.8 
17.6 5.0 
41.2 2.7 
33.5 3.7 
29.6 5.5 
24.9 6.1 
43.4 2.5 
22.6 5.5 
29.7 + 9.1% 4.4 + 1.4% 
RNase protection assays were performed as described under Materials and Methods. Data are expressed as the percent of f ibronectin 
mRNA in each sample that contains the entire indicated exon: the remainder of the mRNA has the entire exon spliced out. Each sample 
represents the RNA derived from the hip or knee art icular  cartilage of one individual patient. All values have been corrected for the 
size of the protected fragments in RNase protection assays. N. normal: OA. osteoarthrit ic.  
isolat ion procedures appear  to give comparable  
results for the spl ic ing pat terns  of f ibronect in 
mRNA from the cart i lage of osteoarthr i t i c  jo ints 
(Table II), we have combined the data from both 
procedures for subsequent  compar isons (Table III). 
Fur thermore,  the amount  of f ibronect in mRNA 
conta in ing exon I I IA  or exon I I IB  does not appear  
to corre late with the age or sex of the pat ient,  
locat ion of the cart i lage sample or the severity of the 
disease (Table III). 
FIBRONECTIN mRNA SPLICING PATTERNS FOR EXON II IA 
AND EXON II IB IN ADULT HUMAN ARTICULAR 
CARTILAGE FROM NORMAL JOINTS 
The cart i lage matr ix  from human [14, 15], canine 
[16-18] and rabbit  [18] osteoarthr i t ic  jo ints contains 
more f ibronectin than  cart i lage from disease-free 
joints. In order to determine whether  changes in 
f ibronectin structure,  resul t ing from al ternat ive 
mRNA splicing, accompany this increase in 
f ibronectin content,  we have examined the exon I I IA 
and exon I I IB spl ic ing pat terns  of f ibronect in 
mRNA isolated from the ar t icu lar  cart i lage of 
normal  and osteoarthr i t i c  joints. The RNase 
protect ion assays (Fig. 2 and Table II I) indicate that  
essential ly no differences in exon I I IB  and exon I I IA 
spl icing patterns  exist between the f ibronect in 
mRNA from the adult  human ar t icu lar  cart i lage of 
normal  and osteoar thr i t i c  jo ints 3. Specifically, 
3Statistically confirmed by ANOVA analysis. 
4.1 ± 2.1% (N= 7) and 4.4 ± 1.4% (N= 8) of fibro- 
nect in mRNA from normal  and osteoar thr i t i c  
cart i lage, respectively, conta in  exon I I IA. Similarly, 
28 .3+7.7% (N=7)  and 29 .7±9.1% (N=8)  of 
f ibronect in mRNA from normal  and osteoar thr i t i c  
cart i lage conta in exon II IB. Thus the s t ruc ture  of 
the addit ional ly  synthesized f ibronect in in osteo- 
ar thr i t ic  cart i lage appears  to be ident ica l  to the 
s t ructure  of the f ibronect in in normal  carti lage. 
These results indicate that  the exon I I IA  and exon 
I I IB spl ic ing pat terns  of f ibronect in mRNA in adult  
human ar t icu lar  cart i lage are not a l tered due to the 
presence of the disease state. 
FIBRONECTIN mRNA SPLICING PATTERNS FOR EXON V 
IN ADULT HUMAN ARTICULAR CARTILAGE FROM 
NORMAL AND OSTEOARTHRITIC JOINTS 
The spl ic ing pat tern  of exon V in f ibronect in 
mRNA from human cells and t issues is much more 
complex than  the spl ic ing of exon I I IA  and exon 
IIIB. Specifically, five potent ia l  splice var iat ions  
exist for exon V in human f ibronect in mRNA 
[reviewed in 1, 2]. This complexi ty  is not easi ly 
amenable to the use of RNase protect ion assays 
for determinat ion  of the exon V spl ic ing pat tern  
in var ious tissues. Therefore, we have uti l ized an 
RT-PCR approach that  has been uti l ized for the 
determinat ion  of exon V spl ic ing pat terns  in var ious 
human cell l ines [26]. Fig. 3(c) shows a schemat ic  
d iagram of the possible exon V spl ic ing pat terns  
and the  corresponding size of the expected 
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PCR products using the 5' and 3' otigonucleotide 
primers described in Materials and Methods. The 
results of RT-PCR assays using total RNA isolated 
directly from the adult human articular cartilage of 
normal and osteoarthritic cartilage are shown in 
Fig. 3(a). All three samples from normal cartilage 
and all four samples from osteoarthritic cartilage 
appear to contain only one exon V splicing variant; 
the variant corresponding to the absence of exon V 
from the fibronectin mRNA. Fibronectin RNA from 
human liver and T98G glioblastoma cells exhibit 
multiple RT-PCR products [Fig. 3(b)] similar to the 
exon V splicing patterns determined previously for 
these samples [26, 28]. The combination of these 
results indicate that the majority of the fibronectin 
mRNA from adult human articular cartilage has the 
entire exon V spliced out and that no differences 
exist in the fibronectin mRNA splicing patterns of 
exon V between the articular cartilage of normal 
and osteoarthritic joints. 
Discuss ion  
Alternative splicing of fibronectin primary 
transcripts during RNA processing generates 
heterogeneity in the structure of fibronectin at the 
protein level. Such differences in RNA splicing are 
often regulated in a tissue-specific and/or develop- 
mental manner, even though the function of this 
protein heterogeneity is largely unknown. Several 
laboratories have observed an increase in fibro- 
nectin protein in the cartilage from osteoarthritic 
joints compared with the cartilage from normal 
joints [14-18]. At the protein level, immunoreactiv- 
ity with exon-specific antibodies to fibronectin 
revealed that 0.7-6.0% and 5-30% of the fibronectin 
in adult human articular cartilage from os- 
teoarthrit ic j oints contains exon IIIA and exon IIIB, 
respectively [19]. However, the structure of 
fibronectin, due to the splicing patterns of exons 
IIIA and IIIB, in adult human articular cartilage 
from normal joints was unknown. Furthermore, no 
information was available on exon V splicing in 
adult human articular cartilage from normal and 
osteoarthritic joints. We have shown in this 
communication that no gross differences exist in the 
fibronectin mRNA splicing patterns for any of 
the alternatively spliced exons (IIIA, IIIB and V) 
between the mRNAs isolated from adult human 
normal and osteoarthritic articular cartilages. 
Thus alterations in the structure of cartilage 
fibronectin do not appear to correlate with the 
increase in fibronectin level associated with the 
disease state. However, examination ofthe tissues by 
in situ hybridization and/or immunofluorescence 
would determine whether or not local changes in 
fibronectin mRNA splicing Patterns exist in the 
focal osteoarthritic areas of the diseased cartilage. 
The RNase protection assays for the splicing 
patterns of exon IIIA and exon IIIB for the 
fibronectin mRNA isolated from adult human 
normal and osteoarthritic cartilage also indicate 
that the fibronectin exon IIIA and exon IIIB splicing 
patterns at the RNA level agree with the amounts of 
fibronectin protein containing the regions encoded 
by these exons in adult human osteoarthrit ic 
cartilage. Thus the alternatively spliced fibronectin 
mRNA in these cartilage tissues appears to be 
equally translated into the associated fibronectin 
isoforms ruling out potential post-transcriptional 
mechanisms that might regulate the final structure 
of fibronectin in the cartilage from normal and 
osteoarthritic joints. 
Finally, several aboratories report the presence 
of little or no fibronectin containing the region 
encoded by exon IIIA in cartilages from various 
species [13, 19, 29, 30] while the fibronectin from 
other tissues largely contains the exon IIIA domain 
[13, 30, 31]. This report demonstrates that the 
fibronectin mRNA from the adult human articular 
cartilage of both normal and osteoarthritic joints 
also contain little or no exon IIIA (only about 4% of 
the fibronectin mRNA contains the exon). 
The combination of these results indicate that 
independent of species, age or type of cartilage, 
nearly all cartilage fibronectin mRNA does not 
contain exon IIIA. Thus the absence of the region 
encoded by exon IIIA in cartilage fibronectin may be 
an important structural feature for fibronectin 
function in all types of cartilage. 
The amount of fibronectin mRNA containing 
exon IIIB in adult human articular cartilage 
(21-39%) is different from the amount containing 
exon IIIB in chick embryonic transient cartilage 
(98-100%). This difference does not appear to result 
from species differences since exon IIIB expression 
in adult chick articular cartilage (30-37%) i s  
identical to the expression i  adult human articular 
cartilage (Gehris and Bennett, unpublished obser- 
vations). Thus the variation in the exon IIIB 
expression i  the fibronectin mRNA from embryonic 
chick transient cartilage and adult human articular 
cartilage may accompany minor differences in the 
overall content of the cartilage matrix due to 
developmental/aging differences and/or types of 
cartilage. For example, tenascin, an anti-adhesive 
molecule, appears to be expressed more highly in 
permanent articular cartilage than in transient 
cartilage that is eventually replaced by bone during 
endochondral ossifcation [32]. Other quantitative 
differences exist in the levels of type II, IX and XI 
collagens during development/aging a d in articular 
(a) 
V 
2645 - 
1605 - 
1198 - -  
676  - 
517  - 
460- -  
396  - 
350  - 
222  - 
179  - 
126  - 
(b) 
0 
I l , ' 
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1 2 3 4 5 6 7 8 9 10 1 2 3 4 
- 796  
- 703  
- 638  
- 436 
(c) Exon V splicing pattern Exon V size (bp) PCR product size (bp) 
0 436 . 
192 638 
267 703 
285 721 
360 796 
Fro. 3. RT-PCR analysis of exon V splicing in fibronectin mRNA from adult human normal and osteoarthritic Cartilage. 
(a) Ethidium bromide stained agarose gelcontaining RT-PCR products resulting from no RNA (lanes 2 and 6) or total RNA 
isolated from normal (lanes 3-5) and osteoarthritic (lanes 7 10) cartilage with 5'and 3' oligonucleotide primers from the 
type III-14 and type 1-10 repeats, respectively, of the human fibronectin gene as described in Materials and Methods. Size 
markers (lane 10) are fragments of pGEM3 digested with Hin f I ,  Rsa I, and Sin I (Promega Biotec). (b) Same as (a) with 
total RNA from normal human liver (lane 1), T98G glioblastoma cells (lane 2), no RNA (lane 3) and size markers (lane 4). 
(c) Schematic diagram of the possible xon V splicing patterns in human fibronectin mRNAs, the size of the corresponding 
exon V fragment, and the expected size of the corresponding PCR product. 
vs t rans ient  cart i lage [for review, see 7]. Finally, the 
levels, types and lengths of side-chains of cart i lage 
proteoglycans also vary  with some of these 
parameters  [for review see 33, 34]. Thus the level of 
exon I I IB  expression in f ibronect in mRNA may 
corre late with any of these other  subtle matr ix  
changes that  occur  dur ing the development /ag ing 
process of var ious cart i lage types. 
Exon V appears  to be complete ly  absent  from all 
of the f ibronect in mRNA from the adult  human 
ar t icu lar  cart i lage of normal  and osteoarthr i t i c  
joints. This resul t  is somewhat  surpr is ing since the 
ent i re exon V is present  in all of the f ibronect in 
mRNA from embryonic  chick t rans ient  cart i lage 
[13]. However, only two spl ic ing var iants  exist for 
exon V in the chick; exon V may ei ther be ent i re ly 
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present  or the first 132 bases may be absent  [31]. 
In other  words, the ent i re  exon V cannot  be 
spl iced out  of chick f ibronect in  mRNA. Interest-  
ingly, exon V in human and rat  f ibronect in conta ins  
two domains active in cell adhes ion [35-37]. One of 
these domains conta ins  an REDV sequence in 
human f ibronect in [38, 39] and an RGDV sequence 
in rat  f ibronect in [40] which resembles the in tegr in  
b ind ing site RGDS. Exon V in chick f ibronect in does 
not  conta in  any sequence resembl ing RGDS, REDV 
or RGDV [31]. Thus the absence of exon V in human 
cart i lage f ibronect in may serve to prevent  adhes ion 
effects in chondrocytes  that  are at t r ibuted to this 
exon in other  cells or t issues. In any event, the 
compl icated nature  of the interact ions in the 
cart i lage extrace l lu lar  matr ix  obviously requires 
fur ther  explorat ion in order  to ful ly unders tand  the 
role of f ibronect in s t ruc tura l  a l terat ions resu l t ing 
from the a l ternat ive spl ic ing of exons I I IA, I I IB  and 
V in cart i lage tissues. 
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